STOCK TITAN
  1. Home
  2. Sec-filings
  3. QTZM
  4. [8-K] Quantumzyme Corp. Reports Material Event

Quantumzyme (QTZM) becomes Quantum Genesis AI Corp. with new QGAI ticker

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Quantumzyme Corp. has formally changed its corporate name to Quantum Genesis AI Corp. following approval by its board on January 7, 2026 and by the holder of 79.56% of the voting power on November 30, 2025. The company filed a Certificate of Amendment with the Nevada Secretary of State on February 11, 2026, making the name change effective upon filing.

The company’s OTC trading symbol will change to “QGAI”, with the name and symbol change taking effect in the market at the open of business on February 17, 2026, as processed and announced by FINRA on February 13, 2026. These changes do not affect shareholder rights, authorized capital, issued and outstanding shares, par value, or the company’s CUSIP number.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What corporate change did Quantumzyme Corp. (QTZM) announce in this 8-K?
Quantumzyme Corp. changed its corporate name to Quantum Genesis AI Corp. after board and majority shareholder approval. The change became effective upon filing a Certificate of Amendment with the Nevada Secretary of State on February 11, 2026.

When will Quantumzyme Corp. begin trading under the new QGAI ticker symbol?
The company will begin trading under the new “QGAI” symbol at the open of business on February 17, 2026. FINRA processed and announced the name and symbol changes on February 13, 2026.

Did the Quantum Genesis AI Corp. name change affect shareholder rights or capital structure?
The filing states the name and symbol changes do not affect shareholder rights. They also do not change the company’s authorized capital, issued and outstanding shares, or par value, leaving the capital structure unchanged.

What shareholder approval supported Quantumzyme Corp.’s name change to Quantum Genesis AI Corp.?
The name change was approved by the holder of 79.56% of the voting power of the company’s outstanding capital stock through a written consent executed on November 30, 2025, providing majority approval.

Will Quantum Genesis AI Corp.’s CUSIP number change with the new name and symbol?
No, the filing states the company’s CUSIP number will not change in connection with the corporate name change to Quantum Genesis AI Corp. and the trading symbol change to QGAI.

What document implements Quantum Genesis AI Corp.’s name change legally?
The name change is implemented through a Certificate of Amendment to the Articles of Incorporation filed with the Nevada Secretary of State on February 11, 2026. This document is attached as Exhibit 3.1.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 13, 2026 (November 30, 2025)

 

QUANTUMZYME CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-56725

 

N/A

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification Number)

 

15656 Bernardo Center Drive Suite 801

San Diego, CA 92127

Tel.: 858-225-2902

 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:  

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

N/A

 

N/A

 

N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

 

 

 

QUANTUMZYME CORP.

Form 8-K

Current Report

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

As previously announced, on January 7, 2026, the Board of Directors of Quantumzyme Corp. (the “Company”) approved (i) an amendment to the Company’s Articles of Incorporation to change the Company’s name from Quantumzyme Corp. to Quantum Genesis AI Corp. (the “Name Change”), and (ii) to change the Company’s OTC stock trading symbol (the “Symbol Change”). On November 30, 2025, the holder of 79.56% of the voting power of the Company’s outstanding capital stock approved the Name Change by written consent.

 

The Company filed a Certificate of Amendment to the Articles of Incorporation (the “Amended Articles”) with the Secretary of State of the State of Nevada on February 11, 2026. The Name Change became effective upon filing. A copy of the Amended Articles is attached hereto as Exhibit 3.1.

 

The Name Change and Symbol Change were processed and announced by FINRA on February 13, 2026, and shall take effect in the market at the open of business on February 17, 2026 (the “Effective Date”). The Company’s trading symbol shall be “QGAI” on the Effective Date.

 

The Name Change and Symbol Change will not affect the rights of shareholders and will not result in any change to the Company’s authorized capital, issued and outstanding shares, or par value. The Company’s CUSIP number will not change in connection with the Name Change and Symbol Change. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No.

 

Description

3.1

 

Certificate of Amendment filed February 11, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).  

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 QUANTUMZYME CORP.
    
Dated: February 13, 2026 /s/ Naveen Krishnarao Kulkarni

 

 

By: Naveen Krishnarao Kulkarni 
  Its: Chief Executive Officer  
    

 

 

3

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Other Documents